JAK2 and neoplasm: Organoids derived from KPN (VillinCreER− KrasG12D/+; Trp53fl/fl; Notch1TG/+) and AKPT (VillinCreER; Apcfl/+; KrasG12D/+; Trp53fl/fl;TgfbrIfl/fl) were utilised to determine the effect of repurposed JAK1/2 inhibitor Ruxolitinib and JAK2/3 inhibitor Tofacitinib due to the high constitutive expression of pSTAT3 within tumor cell nuclei and CMS4 tumor classification (Fig. 1A).